Cambridge Healthtech Instituteの第4回年次

Next-Generation Immunotherapies
次世代の免疫療法

Novel Approaches for Reprogramming the Immune System
免疫系リプログラミング向け新規アプローチ

2025年5月15日 - 16日 EDT(米国東部標準時・夏時間)

免疫療法の分野は近年驚異的な進歩を遂げていますが、標的、デリバリー、有効性、安全性に関する課題は依然として残っています。今後 5〜10 年間で、現在の治療の限界を克服するには、どのような技術や手法が(再)登場して免疫療法の未来を形作るのでしょうか?Cambridge Healthtech Instituteの第4回年次「次世代の免疫療法」会議では、in vivo工学や免疫細胞へのデリバリー、新しいターゲットを特定するAIアプローチ、T細胞エンゲージャー、ウイルスや細菌ベースの免疫療法など、免疫リプログラミングプラットフォームの次なる波について取り上げます。

Sunday, May 11

1:00 pmMain Conference Registration

2:00 pmRecommended Pre-Conference Short Course

SC3: Challenges and Opportunities in Solid Tumor and Autoimmune Disease Therapeutic Innovations

*Separate registration required. See short course page for details.

Tuesday, May 13

6:30 pmRecommended Dinner Short Course

SC5: Targeting the Target: Aligning Target and Biologic Format Biology to Achieve Desired Outcomes

*Separate registration required. See short course page for details.

Thursday, May 15

7:45 amRegistration and Morning Coffee

IN VIVO CAR T ENGINEERING: MOVING INTO THE CLINIC

8:25 am

Chairperson's Remarks

Adrian Bot, MD, PhD, CSO, Executive Vice President, R&D, Capstan Therapeutics

8:30 am

In vivo Engineering of Immune Cells: Update from Umoja Biopharma

David J. Fontana, PhD, Chief Business and Strategy Officer, Umoja BioPharma

9:00 am

In vivo mRNA-Based CAR T Cell Engineering for Treatment of B Cell Disorders

John Rossi, PhD, Vice President, Translational Medicine, Capstan Therapeutics

We developed a novel in vivo anti-CD19 CAR mRNA product (CPTX2309), delivered through CD8-targeted lipid nanoparticles (tLNP). Evaluation in non-human primates speaks to the potential of this platform to achieving immune reset, key to effectively treating B cell-autoimmunity. This sets up the stage for clinical development of CPTX2309 and opens an avenue for development of similar products for broad indications, overcoming the challenges of ex vivo viral-engineered CAR T cells.

9:30 am KEYNOTE PRESENTATION:

In vivo and ex vivo Use of LNP-Mediated Technology to Treat Hematological Disorders

Stefano B. Rivella, PhD, Professor, Pediatrics, Children's Hospital of Philadelphia

Current therapies allow the replacement of diseased hematopoietic stem progenitor cells (HSPC) with gene-engineered or healthy HSPC through bone-marrow transplantation. Starting from ex vivo technologies, we will discuss how targeted lipid nanoparticles (tLNP) carrying messenger RNA (mRNA) can target HSPC and revolutionize how we perform bone-marrow transplantation or directly cure HSPC in vivo

10:00 am Advancing Bispecific Antibody Development: Overcoming Challenges with Innovative Solutions for Target Binding and Functional Assessment 

Speaker to be Announced, Sartorius

Bispecific antibodies (BsAbs) are therapeutic antibodies targeting different antigens or epitopes, enhancing potency and therapeutic effects. Various constructs, like scFv, DARTs, Triomabs, and BiTEs, are being developed for diseases like cancer. Their diverse designs may face structural constraints affecting binding and performance. A major challenge is the lack of technologies for quantitative functional assessment of BsAbs' dual targets, necessitating innovative approaches beyond traditional monoclonal antibodies. This talk will present solutions for efficient biophysical and functional characterization of BsAbs in development.

10:15 am Talk Title to be Announced

Speaker to be Announced, KACTUS

10:30 amCoffee Break in the Exhibit Hall with Poster Viewing

11:15 amTransition to Plenary Fireside Chat

PLENARY FIRESIDE CHAT

11:25 am

Riding the Next Biotech Wave-Trends in Biotech Investments, Partnering, and M&As

PANEL MODERATOR:

Jakob Dupont, MD, Executive Partner, Sofinnova Investments

  • Emerging Biotherapeutic Modalities, Technologies and Innovations- ADCs, radiopharmaceuticals, GLP-1, AI, machine learning, and other exciting trends to watch
  • Introduction to different strategies for investments, M&As, partnering, licensing etc.
  • Investing in platforms versus assets
  • Advice on funding options for start-ups, early to late stage clinical programs, etc.
PANELISTS:

Michal Preminger, PhD, MBA, Regional Head, East North America, Johnson & Johnson Innovation LLC

Shyam Masrani, Partner, Medicxi

Uciane Scarlett, PhD, Former Principal, MPM BioImpact

Anthony B. Barry, PhD, Executive Director, ES&I Lead, Biotherapeutics, Technologies, and Digital, Pfizer Inc.

12:25 pmLuncheon in the Exhibit Hall and Last Chance for Poster Viewing

NEXT-GENERATION IMMUNOTHERAPIES: IN VIVO APPROACHES

1:55 pm

Chairperson's Remarks

Hamideh Parhiz, PharmD, PhD, Research Assistant Professor, Infectious Diseases, University of Pennsylvania

2:00 pm

Increasing the Availability of CAR T Cells

Frederic B. Thalheimer, PhD, Molecular Biotechnology & Gene Therapy, Paul Ehrlich Institut

This presentation focusses on two upcoming strategies facilitating CAR T cell generation. Short-term CAR T cells accelerate production times but may bear an increased risk for severe cytokine release syndrome. In vivo CAR T generation relies on T cell-specific vectors as off-the-shelf product while proof for clinical benefit remains to be provided.

2:30 pm Talk Title to be Announced

Jagesh V. Shah, PhD, SVP, Head of Platform, Stealth Biotech, Flagship Pioneering

3:00 pm

mRNA Delivered In Vivo CAR for Myeloid Cells to Combat Solid Tumors

Yuxiao Wang, PhD, Co-Founder & Vice President, Discovery Research, Myeloid Therapeutics

We introduce a novel class of innate immune receptor-based CARs designed to program myeloid cells in vivo using mRNA/LNP, overcoming limitations of current CAR therapies in solid tumors. Preclinical data demonstrate robust anti-tumor efficacy, leading to the initiation of first-in-human clinical trials for TROP2 and GPC3-targeting CARs, highlighting significant potential for advancing cancer immunotherapy.

3:30 pmSponsored Presentation (Opportunity Available)

4:00 pmNetworking Refreshment Break

4:30 pm

Engineering Chimeric Antigen Receptor for mRNA CAR T

Huan Yang, PhD, Associate Principal Scientist, Discovery Biologics, Merck & Co. Inc.

Tonic signaling from CAR expression is proposed to be associated with CAR T exhaustion. Our study describes an in vitro model for investigating tonic signaling in mRNA CAR T cells, which has not been fully characterized. Among approximately 80 tested permutations of structural elements, a few optimal CAR designs showed improved antigen-dependent T cell immune responses in vitro. Additionally, several formats of mRNA were also evaluated for CAR expression persistence.

5:00 pm

Targeted Fusogens Enable Potent in vivo CAR T Generation with High Cell-Specificity

Kyle M. Trudeau, PhD, Executive Director, Innovation, Sana Biotechnology, Inc.

5:15 pm

Adaptive Protein Evolution X-attention (APEX) Model for Augmented CAR Discovery

Jenny Wei, PhD, Senior Director, R&D Informatics and Technology, Kite Pharma

To improve the efficiency of design and development of CAR constructs, we built the APEX model by fine tuning protein-language model ESM2 with a dataset comprised of binder (scFv, Fab, and VHH) and antigen pairs curated from the Structural Antibody Database. The model achieved robust performance on affinity prediction and can be expanded for other property prediction. Model adoption into CAR campaign facilitates binder prioritization to reduce discovery cycle time.

5:30 pmPresentation to be Announced

6:00 pmClose of Day

Friday, May 16

7:15 amRegistration Open

INTERACTIVE DISCUSSIONS

7:30 amInteractive Discussions

Interactive Discussions are informal, moderated discussions, allowing participants to exchange ideas and experiences and develop future collaborations around a focused topic. Each discussion will be led by a facilitator who keeps the discussion on track and the group engaged. To get the most out of this format, please come prepared to share examples from your work, be a part of a collective, problem-solving session, and participate in active idea sharing. Please visit the Interactive Discussions page on the conference website for a complete listing of topics and descriptions.

BREAKOUT DISCUSSION:

ML to Optimize Immune Cell Engagers

Winston Haynes, PhD, Head, Data Science & Machine Learning, LabGenius Ltd.

  • Dive into the challenges with engineering immune cell engagers where machine learning might have an impact (i.e. development speed, therapeutic efficacy, clinical safety)
  • Discuss the data and models needed to develop superior therapies. 
  • Highlight different machine learning methods being applied to the design and optimisation of immune cell engagers. 
  • Explore future directions for machine learning in immune cell engagers. 

COMPUTATIONAL AND ML APPROACHES TO T CELL ENGAGERS

8:25 am

Chairperson's Remarks

Caleb A. Lareau, PhD, Assistant Professor, Memorial Sloan Kettering Cancer Center

8:30 am

Next-Generation Immunotherapies Unlocked via Petabyte-Scale Analyses

Caleb A. Lareau, PhD, Assistant Professor, Memorial Sloan Kettering Cancer Center

The accumulation of biological data, including DNA sequencing data in the Sequence Read Archive (SRA) and protein structures in the Protein Data Base (PDB) are the primary substrates underlying recent advances in the use of artificial intelligence in biological systems. Here, we present our lab's recent work on both mining and extrapolating from these repositories of petabyte-scale data, including our identification of potential new modalities for immunotherapy.

9:00 am FEATURED PRESENTATION:

Leveraging Single-Cell Sequencing to Identify Highly Precise T-Cell Engager Targets

Alexander J Martinko, PhD, Senior Director, Antibody Engineering & Design, Cartography Biosciences Inc.

T-cell engagers (TCEs) are a promising approach for solid tumors, with the first TCE for a major solid tumor approved in 2024. However, progress is limited by a lack of tumor-selective targets that maximize efficacy while minimizing on-target, off-tumor toxicity. We developed the ATLAS platform, a curated single-cell RNA sequencing resource that leverages both healthy and tumor-derived datasets to identify highly precise TCE targets. Using ATLAS, we discovered LY6G6D as a tumor-specific colorectal cancer (CRC) target, guiding the engineering of a best-in-class LY6G6D TCE for CRC.

9:30 am

Bispecific T Cell Engager Targeting a Novel pHLA Target

Ryan L. Stafford, PhD, Executive Director, Protein Engineering, 3T Biosciences Inc.

T cells recognize intracellular targets presented by HLA to enable potent anti-tumor immune responses, and these targets can be leveraged to generate off-the-shelf therapeutics using T cell-bispecific engagers to treat a broad patient population. We've developed 3T-TRACE to rapidly identify the antigens of orphan T cells from patient tumors and 3T-PRIME, a TCR mimetic platform to rapidly generate potent and specific binders for therapeutic development.

10:00 amSponsored Presentation (Opportunity Available)

10:30 amNetworking Coffee Break

11:00 am

A Novel T Cell Engager Platform Empowering Innovative and Effective Immunotherapies

Ahmet S. Vakkasoglu, PhD, Associate Director, Biologics Discovery and Innovation, Cue Biopharma

Immuno-STATs represent a Fc fusion molecules capable of engaging, activating, and amplifying disease-specific T-cells. Our leading clinical candidate, CUE-101, specifically targets HPV E7-specific T cells and has shown remarkable efficacy in patients with advanced head and neck cancer. With this clinical success and our platform's proven safety, we introduce the Immuno-STAT platform. It enables the targeting of various tumor types in addition to AI applications.

11:30 am

Non-Pathogenic E. coli Displaying Decoy-Resistant IL18 Mutein Boosts Antitumor and CAR NK Cell Responses

Jiahe Li, PhD, Assistant Professor, Biomedical Engineering, University of Michigan

The tumor microenvironment can inhibit the efficacy of cancer therapies through mechanisms such as poor trafficking and exhaustion of immune cells. Here, to address this challenge, we exploited the safety, tumor tropism and ease of genetic manipulation of non-pathogenic Escherichia coli (E. coli) to deliver key immune-activating cytokines to tumors via surface display on the outer membrane of E. coli K-12 DH5a.

12:00 pm

Cancer-Specific Targeting of Vesicular Stomatitis Virus

Kepeng Wang, PhD, Assistant Professor, Department of Immunology, University of Connecticut

Oncolytic viral therapies for cancers are frequently limited to intralesional injection due to non-specific localization of systemically injected viral particles. We developed a modified vesicular stomatitis virus (VSV) that harbors tumor-activating moiety. This novel virus preferentially distributes to tumor tissues and showed enhanced safety compared to wild-type VSV. When incorporated with a single chain, biologically active interleukin-12 (IL-12)-the novel virus mounts effective control against tumor growth.

12:30 pmClose of Summit

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。

Choose your language
Traditional Chinese
Simplified Chinese
Korean
English

更新履歴
2025/03/21
アジェンダ・講演者・スポンサー更新

表示する:

Engineering
工学ストリーム
Oncology
腫瘍ストリーム
Bispecific Antibodies
多重特異性ストリーム
Immunotherpary
免疫療法ストリーム
Expression
発現ストリーム
Analytical
分析法ストリーム
Immunogenicity
免疫原性ストリーム
Emerging Modalities
新興治療ストリーム
Machine Learning Stream
機械学習ストリーム

Premier Sponsors

FairJourneyBiologics GenScript-CRO Integral-Molecular_NEW  LONZAOmniAbUnchainedLabs
会議の詳細はこちらをご参照ください